Abstract 411P
Background
The cancer, which claims a million deaths per annum across India is a major concern due to presentation in later stages, owing to lack of awareness and structured screening programs. The fragmented screening happens through hospitals (HBS), rural camps by screening buses (CSB), awareness programs, and augmented self-examination (ASE) protocols using AI. This research is aimed to empower cancer screening strategies.
Methods
The effective analysis is based on the number of cancer cases detected and treated effectively. Cost data were collected as a combination of CAPEX and OPEX to do a camp and cost is derived per test using key informant interviews, patient surveys, and other publicly available data sources. A hypothetical cohort of 5,00,000 patients was assumed for assessing each strategy. One-way, two-way, and probabilistic sensitivity analyses were performed to test the robustness of the result. The methods selected were HBS, CSB &ASE.
Results
The results showed augmented self-examination is the best strategy followed by education and lastly screening vehicles. One-way analysis showed that the results were sensitive to the labor cost, but the two-way analysis showed that results are not sensitive to cancer burden. The cost of ASE for 3 cancers (oral, cervical breast) per person is INR 150, for CSB 1200 INR, and for HBS its 650 INR.
Conclusions
ASE is the way forward in developing nations followed by empowering the community health centers and the least effective is cancer screening buses.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06